Atypical Multiple Sclerosis Overlapping Features of Neuromyelitis Optica Spectrum Disorders (NMOSD).

Area of Science:

• Neurology
• Immunology
• Neuroinflammation

Background:

• Inflammatory demyelinating diseases (IDD) like multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) share overlapping clinical and radiological features.
• Misdiagnosis between MS and NMOSD can lead to ineffective or detrimental treatments, as therapies for MS may exacerbate NMOSD.
• Accurate differentiation is critical for appropriate patient management and therapeutic selection.

Purpose of the Study:

• To highlight the importance of precise diagnosis in atypical inflammatory demyelinating diseases (IDD).
• To emphasize the potential risks associated with misdiagnosing neuromyelitis optica spectrum disorders (NMOSD) as multiple sclerosis (MS).
• To underscore the necessity of recognizing diagnostic red flags in suspected MS cases due to overlap with NMOSD.

Main Methods:

• Case presentation of a 20-year-old male with acute quadriparesis and hyperreflexia.
• Utilized brain and cervical MRI to identify T2-weighted hyperintensities.
• Conducted cerebrospinal fluid (CSF) analysis for oligoclonal bands and serum testing for AQP4-IgG antibodies.
• Applied the 2017 revised McDonald criteria for MS diagnosis.
• Administered treatments including intravenous methylprednisolone, therapeutic plasma exchange, and rituximab.

Main Results:

• The patient presented with symptoms suggestive of a demyelinating event.
• MRI revealed T2-weighted hyperintensities in periventricular and corticomedullary junction areas.
• CSF analysis showed CSF-restricted oligoclonal bands, while serum AQP4-IgG was negative.
• Despite initial MS diagnosis and treatment, the patient showed significant improvement (EDSS score from 8.5 to 3) after rituximab therapy, suggesting a potential misdiagnosis or atypical presentation.
• The case underscores the diagnostic challenges in differentiating MS from NMOSD.

Conclusions:

• Accurate diagnosis of atypical IDD is crucial to avoid harmful therapies and ensure timely, effective treatment.
• Vigilance for diagnostic red flags is essential in MS due to its overlap with NMOSD.
• Prompt and correct diagnosis leads to improved patient outcomes, as demonstrated by the significant EDSS score improvement with rituximab.